Benfotiamine: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews

Overview

Benfotiamine is similar to thiamine (vitamin B1), but is absorbed by the body better than thiamine. The body changes benfotiamine to thiamine.

Since the body absorbs benfotiamine better than thiamine, benfotiamine can increase how much thiamine is in the body. This may help prevent or treat certain symptoms or diseases caused by low thiamine levels. Benfotiamine can be made by certain plants, such as garlic and onion. It can also be made in a lab.

People use benfotiamine for nerve damage caused by diabetes (diabetic neuropathy). It is also used for alcohol use disorder, Alzheimer disease, arthritis, and other conditions, but there is no good scientific evidence to support most of these uses.

Uses & Effectiveness

Possibly Effective for

Nerve pain in people with diabetes (diabetic neuropathy). Taking benfotiamine by mouth, with or without vitamin B6 and B12, can improve pain and other symptoms of nerve damage caused by diabetes.

Possibly Ineffective for

Kidney damage in people with diabetes (diabetic nephropathy). Taking benfotiamine by mouth does not seem to improve markers of kidney damage in people with diabetes who have kidney disease.

There is interest in using benfotiamine for a number of other purposes, but there isn't enough reliable information to say whether it might be helpful.

Side Effects

When taken by mouth: Benfotiamine is likely safe at doses of up to 600 mg daily for up to 24 weeks. Side effects are rare, but some people have reported stomach problems and skin rashes.

Special Precautions and Warnings

When taken by mouth: Benfotiamine is likely safe at doses of up to 600 mg daily for up to 24 weeks. Side effects are rare, but some people have reported stomach problems and skin rashes.

Pregnancy and breast-feeding: There isn't enough reliable information to know if benfotiamine is safe to use when pregnant or breast-feeding. Stay on the safe side and avoid use.

Interactions

We currently have no information for Benfotiamine overview.

Dosing

Benfotiamine is most often used by adults in doses of 150-600 mg by mouth daily for up to 6 months. Speak with a healthcare provider to find out what dose might be best for a specific condition.

View References

REFERENCES:

Babaei-Jadidi R, Karachalias N, Ahmed N, et al. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes. 2003;52:2110-20.

Winkler, G., Pal, B., Nagybeganyi, E., Ory, I., Porochnavec, M., and Kempler, P. Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy. Arzneimittelforschung. 1999;49(3):220-224.

Stracke, H., Lindemann, A., and Federlin, K. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol.Diabetes 1996;104(4):311-316.

Bitsch R, Wolf M, Möller J, Heuzeroth L, Grüneklee D. Bioavailability assessment of the lipophilic benfotiamine as compared to a water-soluble thiamin derivative. Ann Nutr Metab 1991;35(5):292-6.

Loew D. Pharmacokinetics of thiamine derivatives especially of benfotiamine. Int J Clin Pharmacol Ther 1996;34(2):47-50.

Simeonov S, Pavlova M, Mitkov M, Mincheva L, Troev D. Therapeutic efficacy of "Milgamma" in patients with painful diabetic neuropathy. Folia Med (Plovdiv) 1997;39(4):5-10.

Woelk H, Lehrl S, Bitsch R, Köpcke W. Benfotiamine in treatment of alcoholic polyneuropathy: an 8-week randomized controlled study (BAP I Study). Alcohol Alcohol 1998;33(6):631-8.

Greb A, Bitsch R. Comparative bioavailability of various thiamine derivatives after oral administration. Int J Clin Pharmacol Ther 1998 Apr;36(4):216-21.

Ziems M, Netzel M, Bitsch I. Biokinetic parameters and metabolism of S-benzoylthiamine-O-monophosphate. Biofactors. 2000;11(1-2):109-10.

Frank T, Bitsch R, Maiwald J, Stein G. High thiamine diphosphate concentrations in erythrocytes can be achieved in dialysis patients by oral administration of benfotiamine. Eur J Clin Pharmacol 2000;56(3):251-7.

Haupt E, Ledermann H, Köpcke W. Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther 2005;43(2):71-7. Erratum in: Int J Clin Pharmacol Ther 2005;43(6):304.

Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003;9(3):294-9.

Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 2008;116(10):600-5.

Schmid U, Stopper H, Heidland A, Schupp N. Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro. Diabetes Metab Res Rev 2008;24(5):371-7.

Du X, Edelstein D, Brownlee M. Oral benfotiamine plus alpha-lipoic acid normalises complication-causing pathways in type 1 diabetes. Diabetologia 2008;51(10):1930-2.

Alkhalaf A, Klooster A, van Oeveren W, et al. A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 2010;33(7):1598-601.

Pan X, Gong N, Zhao J, et al. Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain 2010;133(Pt 5):1342-51.

Fraser DA, Diep LM, Hovden IA, et al. The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care 2012;35(5):1095-7.

Alkhalaf A, Kleefstra N, Groenier KH, et al. Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy. PLoS One 2012;7(7):e40427.

Sun XJ, Zhao L, Zhao N, et al. Benfotiamine prevents increased ß-amyloid production in HEK cells induced by high glucose. Neurosci Bull 2012;28(5):561-6.

Shoeb M, Ramana KV. Anti-inflammatory effects of benfotiamine are mediated through the regulation of the arachidonic acid pathway in macrophages. Free Radic Biol Med 2012;52(1):182-90.

Syngle A, Vohra K, Garg N, Kaur L, Chand P. Advanced glycation end-products inhibition improves endothelial dysfunction in rheumatoid arthritis. Int J Rheum Dis 2012;15(1):45-55.

Harisa GI. Benfotiamine enhances antioxidant defenses and protects against cisplatin-induced DNA damage in nephrotoxic rats. J Biochem Mol Toxicol 2013;27(8):398-405.

Stirban A, Pop A, Tschoepe D. A randomized, double-blind, crossover, placebo-controlled trial of 6 weeks benfotiamine treatment on postprandial vascular function and variables of autonomic nerve function in type 2 diabetes. Diabet Med 2013;30(10):1204-8.

Garg S, Syngle A, Vohra K. Efficacy and tolerability of advanced glycation end-products inhibitor in osteoarthritis: a randomized, double-blind, placebo-controlled study. Clin J Pain 2013;29(8):717-24.

Manzardo AM, He J, Poje A, Penick EC, Campbell J, Butler MG. Double-blind, randomized placebo-controlled clinical trial of benfotiamine for severe alcohol dependence. Drug Alcohol Depend 2013;133(2):562-70.

Xie F, Cheng Z, Li S, et al. Pharmacokinetic study of benfotiamine and the bioavailability assessment compared to thiamine hydrochloride. J Clin Pharmacol 2014;54(6):688-95.

Manzardo AM, Pendleton T, Poje A, Penick EC, Butler MG. Change in psychiatric symptomatology after benfotiamine treatment in males is related to lifetime alcoholism severity. Drug Alcohol Depend 2015;152:257-63.

Sugimori N, Espinoza JL, Trung LQ, et al. Paraptosis cell death induction by the thiamine analog benfotiamine in leukemia cells. PLoS One 2015;10(4):e0120709.

Pan X, Chen Z, Fei G, et al. Long-term cognitive improvement after benfotiamine administration in patients with Alzheimer's disease. Neurosci Bull 2016;32(6):591-6.

Berrone E, Beltramo E, Solimine C, Ape AU, Porta M. Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem 2006;281(14):9307-13.

Pomero F, Molinar Min A, La Selva M, Allione A, Molinatti GM, Porta M. Benfotiamine is similar to thiamine in correcting endothelial cell defects induced by high glucose. Acta Diabetol 2001;38(3):135-8.

Beltramo E, Berrone E, Buttiglieri S, Porta M. Thiamine and benfotiamine prevent increased apoptosis in endothelial cells and pericytes cultured in high glucose. Diabetes Metab Res Rev 2004;20(4):330-6.

Gibson GE, Luchsinger JA, Cirio R, et al. Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial. J Alzheimers Dis. 2020;78(3):989-1010.

Sheng L, Cao W, Lin P, et al. Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects. Drug Des Devel Ther. 2021;15:1101-1110.

Stirban OA, Zeller-Stefan H, Schumacher J, et al. Treatment with benfotiamine in patients with diabetic sensorimotor polyneuropathy: A double-blind, randomized, placebo-controlled, parallel group pilot study over 12?months. J Diabetes Complications. 2020;34(12):107757.

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is licensed from Therapeutic Research Center, LLC. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
Licensed from Therapeutic Research Center, LLC
Copyright © 1995-2025 by Therapeutic Research Center, LLC. All Rights Reserved.